BioNTech SE : FY review – declining COVID sales weigh on results
>Sales slightly above, bottom-line below expectations due to lower Covid sales - Sales came in at € 4,278m (y-o-y -75%), slightly above our estimates of € 4,179m and those of the consensus (VisibleAlpha) of € 4,203m but are impacted by the declining Covid business. Operating profit amounted to € 690m (- 94%) notably below our estimates of € 796m and those of the consensus of € 906m. R&D expenses in 2023 totalled € 1,783m (+16%) compared with our expectations of € 1,89...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.